20 research outputs found
Will Africans take COVID-19 vaccination?
The economic and humanistic impact of COVID-19 pandemic is enormous globally. No
definitive treatment exists, hence accelerated development and approval of COVID-19 vaccines,
offers a unique opportunity for COVID-19 prevention and control. Vaccine hesitancy
may limit the success of vaccine distribution in Africa, therefore we assessed the potentials
for coronavirus vaccine hesitancy and its determinants among Africans. An online crosssectional
African-wide survey was administered in Arabic, English, and French languages.
Questions on demographics, self-reported health status, vaccine literacy, knowledge and
perception on vaccines, past experience, behavior, infection risk, willingness to receive and
affordability of the SARS-COV-2 vaccine were asked. Data were subjected to descriptive and inferential statistics. A total of 5,416 individuals completed the survey. Approximately,
94% were residents of 34 African countries while the other Africans live in the Diaspora.
Only 63% of all participants surveyed were willing to receive the COVID-19 vaccination as
soon as possible and 79% were worried about its side effects. Thirty-nine percent expressed
concerns of vaccine-associated infection. The odds of vaccine hesitancy was 0.28 (95% CI:
0.22, 0.30) among those who believed their risk of infection was very high, compared to
those who believed otherwise. The odds of vaccine hesitancy was one-fifth (OR = 0.21,
95% CI: 0.16, 0.28) among those who believed their risk of falling sick was very high, compared
to those who believed their risk of falling very sick was very low. The OR of vaccine
hesitancy was 2.72 (95% CI: 2.24, 3.31) among those who have previously refused a vaccine
for themselves or their child compared to counterparts with no self-reported history of
vaccine hesitancy. Participants want the vaccines to be mandatory (40%), provided free of
charge (78%) and distributed in homes and offices (44%). COVID-19 vaccine hesitancy is
substantial among Africans based on perceived risk of coronavirus infection and past
experiences.http://www.plosone.orgam2022Veterinary Tropical Disease
Will Africans take COVID-19 vaccination?
The economic and humanistic impact of COVID-19 pandemic is enormous globally. No definitive treatment exists, hence accelerated development and approval of COVID-19 vaccines, offers a unique opportunity for COVID-19 prevention and control. Vaccine hesitancy may limit the success of vaccine distribution in Africa, therefore we assessed the potentials for coronavirus vaccine hesitancy and its determinants among Africans. An online cross-sectional African-wide survey was administered in Arabic, English, and French languages. Questions on demographics, self-reported health status, vaccine literacy, knowledge and perception on vaccines, past experience, behavior, infection risk, willingness to receive and affordability of the SARS-COV-2 vaccine were asked. Data were subjected to descriptive and inferential statistics. A total of 5,416 individuals completed the survey. Approximately, 94% were residents of 34 African countries while the other Africans live in the Diaspora. Only 63% of all participants surveyed were willing to receive the COVID-19 vaccination as soon as possible and 79% were worried about its side effects. Thirty-nine percent expressed concerns of vaccine-associated infection. The odds of vaccine hesitancy was 0.28 (95% CI: 0.22, 0.30) among those who believed their risk of infection was very high, compared to those who believed otherwise. The odds of vaccine hesitancy was one-fifth (OR = 0.21, 95% CI: 0.16, 0.28) among those who believed their risk of falling sick was very high, compared to those who believed their risk of falling very sick was very low. The OR of vaccine hesitancy was 2.72 (95% CI: 2.24, 3.31) among those who have previously refused a vaccine for themselves or their child compared to counterparts with no self-reported history of vaccine hesitancy. Participants want the vaccines to be mandatory (40%), provided free of charge (78%) and distributed in homes and offices (44%). COVID-19 vaccine hesitancy is substantial among Africans based on perceived risk of coronavirus infection and past experiences
Global patient outcomes after elective surgery: prospective cohort study in 27 low-, middle- and high-income countries.
BACKGROUND: As global initiatives increase patient access to surgical treatments, there remains a need to understand the adverse effects of surgery and define appropriate levels of perioperative care. METHODS: We designed a prospective international 7-day cohort study of outcomes following elective adult inpatient surgery in 27 countries. The primary outcome was in-hospital complications. Secondary outcomes were death following a complication (failure to rescue) and death in hospital. Process measures were admission to critical care immediately after surgery or to treat a complication and duration of hospital stay. A single definition of critical care was used for all countries. RESULTS: A total of 474 hospitals in 19 high-, 7 middle- and 1 low-income country were included in the primary analysis. Data included 44 814 patients with a median hospital stay of 4 (range 2-7) days. A total of 7508 patients (16.8%) developed one or more postoperative complication and 207 died (0.5%). The overall mortality among patients who developed complications was 2.8%. Mortality following complications ranged from 2.4% for pulmonary embolism to 43.9% for cardiac arrest. A total of 4360 (9.7%) patients were admitted to a critical care unit as routine immediately after surgery, of whom 2198 (50.4%) developed a complication, with 105 (2.4%) deaths. A total of 1233 patients (16.4%) were admitted to a critical care unit to treat complications, with 119 (9.7%) deaths. Despite lower baseline risk, outcomes were similar in low- and middle-income compared with high-income countries. CONCLUSIONS: Poor patient outcomes are common after inpatient surgery. Global initiatives to increase access to surgical treatments should also address the need for safe perioperative care. STUDY REGISTRATION: ISRCTN5181700
<span style="font-size:11.0pt;mso-bidi-font-size: 10.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Roman"; mso-ansi-language:EN-GB;mso-fareast-language:EN-US;mso-bidi-language:AR-SA" lang="EN-GB">Endothelium-dependent and independent vasorelaxant effects of aqueous extract of <i style="mso-bidi-font-style:normal">Tridax procumbens</i> Lin. leaf in rat aortic rings</span>
883-888Tridax<i style="mso-bidi-font-style:
normal"> procumbens leaf extract
induced aortic relaxation in a concentration-dependent manner, for both phenylephrine (PE) and KCl- induced contractions in
isolated rat aortic rings. The relaxation effect of the extract on PE-induced
contraction was 57% greater than that on KCl- induced contraction. The extract caused dose-dependent relaxations in precontracted
isolated rat aorta with phenylephrine; the relaxation
was attenuated by the removal of endothelium. However, the relaxation
responses to sodium nitroprusside were not significantly abolished by the
removal of endothelium.
The vasorelaxatory effect of the extract was completely abolished in presence
of L-NAME. The results indicate that the vasorelaxant effect of T. procumbens extract is probably
mediated by both endothelium-dependent and-independent mechanisms